TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17688075
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Study: 17688075
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Study: 17688075
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Study: 17688075
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Study: 26999644
Drug: Higher hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher hydrocortisone dose (0.4-0.6 mg/kg body weight)
Study: 26999644
Drug: Lower hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower hydrocortisone dose (0.2-0.3 mg/kg body weight)
Study: 21810288
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH)
Study: 21810288
Drug: Low-dose oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL)
Study: 21810288
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH) in responders
Study: 17581195
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of IL-5 (10 microg via nebulizer)
Study: 23952947
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs
Study: 1290631
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination screening (first round)
Study: 1290631
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination screening (second round)
Study: 6147451
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement group
Study: 18805677
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI treatment
Study: 30138013
Drug: Treatment remission
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment remission
Study: 9695995
Drug: Ribavirin alone
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Study: 9695995
Drug: Ribavirin plus
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin plus interferon alfa n‐3 for 6 months at the above doses
Study: 9695995
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Study: 31485457
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus low-dose metformin (VLDM)
Study: 31485457
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (HDM)
Study: 26735057
Drug: Closed-suction drains
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed-suction drains in the subcutaneous tissue
Study: 22156332
Drug: Single-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose pregabalin (150 mg before surgery)
Study: 15363813
Drug: Night-time graded-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time graded-release diltiazem (GRD) 360 mg
Study: 15363813
Drug: Morning amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning amlodipine 5 mg
Study: 12972704
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic chemotherapy
Study: 10604299
Drug: Topical carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical carteolol hydrochloride 1.0%
Study: 7577850
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg daily for 8 weeks, then 400 mg for 16 weeks)
Study: 7577850
Drug: Gestrinone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (2.5 mg twice a week for 24 weeks)
Study: 2036187
Drug: Dexamethasone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (single intravenous dose)
Study: 31250761
Drug: Viola odorata
Normalized name: VIOLA ODORATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viola odorata L. oil (20 drops) applied to the peripheral margin of the umbilicus
Study: 31250761
Drug: Viola odorata
Normalized name: VIOLA ODORATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viola odorata L. oil
Study: 19900993
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin (2000 mg)
Study: 19900993
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus repaglinide (6 mg)
Study: 17893258
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type 1 receptor blockade (losartan 200 mg) during hyperinsulinaemic euglycaemic clamp (AT-HEC)
Study: 27603954
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate placebo (3 g day-1)
Study: 23390066
Drug: 12-session reality
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-session reality therapy drug treatment program
Study: 24620447
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (OM 40/AML 10/HCTZ 25 mg)
Study: 24620447
Drug: Dual therapies
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapies (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, AML 10/HCTZ 25 mg)
Study: 1858154
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy
Study: 24620447
Drug: Dual therapies
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapies
Study: 22503212
Drug: Cinacalcet 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 100 mg
Study: 17323180
Drug: Daily bisphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bisphosphonate (alendronate 10 mg/day or risedronate 5 mg/day)
Study: 9663484
Drug: Anti-TNFalpha monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNFalpha monoclonal antibody treatment
Study: 8174061
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX) with brachytherapy; HFX doses of 1.2 Gy administered twice daily, total dose to the whole pelvis 24-48 Gy, followed by one or two intracavitary applications to deliver a total minimum dose of 85 Gy at point A and 65 Gy to lateral pelvic nodes.
Study: 2883990
Drug: Topical levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobunolol 0.5%
Study: 2883990
Drug: Topical metipranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metipranolol 0.6%
Study: 8746886
Drug: New chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: New chemotherapy
Study: 27860366
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium citrate (1 mL)
Study: 27860366
Drug: Physiological sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological sodium chloride solution (1 mL, internal control)
Study: 21486801
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (arginase inhibition plus L-arginine)
Study: 11387588
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (twice weekly group exercise)
Study: 3115372
Drug: HIV counselling
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV counselling and antibody testing during the campaign periods
Study: 3115372
Drug: HIV counselling
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV counselling and antibody testing
Study: 17184491
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg twice daily for 8 weeks
Study: 7814635
Drug: Lipopeptide-based therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopeptide-based therapeutic vaccine (5 and 50 micrograms)
Study: 2108855
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg rt-PA plus heparin over 4 h
Study: 2108855
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg rt-PA over 8 h, repeated in 24 h
Study: 2900919
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus heparin
Study: 2108855
Drug: 4-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-h infusion of rt-PA
Study: 465276
Drug: Rapid release
Normalized name: Mapap Rapid Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid release oxprenolol (160 mg)
Study: 788749
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release oxprenolol (160 mg)
Study: 29980388
Drug: Belief that
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief that the vaccine is safe
Study: 28965384
Drug: Phloroglucinol combined
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol combined with parecoxib (80 mg phloroglucinol qd plus 40 mg parecoxib bid for 3 days)
Study: 28965384
Drug: Phloroglucinol only
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol only (80 mg phloroglucinol qd for 3 days)
Study: 17345837
Drug: levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocetirizine 5 mg
Study: 375838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no low-dose heparin)
Study: 31761458
Drug: No game,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No game, oral information at the outpatient clinic, current standard of care (Group C)
Study: 19543129
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg
Study: 21435024
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light treatment, three times weekly for four weeks
Study: 22079052
Drug: Intraoral myofascial
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral myofascial therapy plus education and self-care exercises (IMTESC)
Study: 18701270
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 500 mg for 20-29 kg, 750 mg for 30-39 kg, 1000 mg for 40-49 kg, 1250 mg for >50 kg once a week for 8 weeks
Study: 17664376
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment
Study: 28589472
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 7 days
Study: 28589472
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + saline solution (SSL) for 14 days
Study: 24722260
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg over 10 minutes followed by a continuous infusion of 0.5 μg/kg/h throughout surgery)
Study: 12424553
Drug: LI 160
Normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI 160 (600 mg/day)
Study: 8577017
Drug: Delayed parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed parenteral nutrition (PN) at day 5, n = 5
Study: 31950384
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (SEGT) combined with oncologic treatment (BRBC)
Study: 30771790
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 600 mg/d for 3 months
Study: 21967242
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (hypoglycemic and antihypertensive agents)
Study: 21967242
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents)
Study: 21967242
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and vitamin E)
Study: 21967242
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and compound salvia tablets)
Study: 15469774
Drug: Raloxifene (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (pooled doses)
Study: 9840853
Drug: 5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg of 0.35% lidocaine with 1:1,000,000 epinephrine
Study: 9840853
Drug: 5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg of saline with 1:1,000,000 epinephrine
Study: 2684698
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (2 mg)
Study: 2684698
Drug: PGE2 tablet
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 tablet (3 mg)
Study: 30807822
Drug: Lung dose
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung dose ≥800 cGy
Study: 30807822
Drug: Lung dose
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung dose <800 cGy
Study: 25257861
Drug: Intravenous elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous elemental iron (40 mg) administered at all three hemodialysis sessions in the first week (IW1 group: n=57)
Study: 25257861
Drug: Intravenous elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous elemental iron (40 mg) administered in the third week (IW3 group: n=53)
Study: 22717454
Drug: Etrolizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab (0.5 mg/kg SC, n=4)
Study: 22717454
Drug: Etrolizumab (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab (3.0 mg/kg SC, n=4)
Study: 22717454
Drug: Etrolizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab (all doses in MD stage)
Study: 12556011
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and antibiotic therapy (n=8)
Study: 8849475
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antibiotics for POD
Study: 8849475
Drug: MRI three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI three months after treatment
Study: 7006558
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and IPT
Study: 31278280
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 100 mg
Study: 31278280
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 300 mg
Study: 31278280
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1000 mg
Study: 31277780
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT)
Study: 20031380
Drug: Nut diet
Normalized name: Coconut diethanolamide
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut diet (30 g/day of raw nuts)
Study: 3978008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no infusion)
Study: 7867675
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195 250 mg
Study: 2670019
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (ESTRADERM TTS‐50), 50 micrograms/day
Study: 2670019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medroxyprogesterone 10 mg/day for 12 days)
Study: 28119433
Drug: AURAS‐AF software
Approvals — FDA: no, EMA: no, PMDA: no
Description: AURAS‐AF software tool for automated risk assessment and reminders for OAC treatment.
Study: 26153191
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of mean depression level at post treatment between both groups.
Study: 24350936
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other oral antidiabetic agents)
Study: 15111514
Drug: Human Soluble
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Soluble Insulin (HI)
Study: 2892260
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg
Study: 12180579
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg
Study: 2801224
Drug: Antibiotics (trimethoprim)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics (trimethoprim) given as single dose or as a conventional 7-day regime
Study: 794090
Drug: 0.05% solution
Normalized name: Equate Nasal Spray 0.05% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% solution of N-monochloroglycine (GK-101) applied under pressure
Study: 8651535
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution of normal saline
Study: 794090
Drug: GK-101 solution
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GK-101 solution in conjunction with the pump system
Study: 794090
Drug: GK-101 solution
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GK-101 solution
Study: 19935122
Drug: Tobramycin 0.3%,
Normalized name: Tobramycin 0.3%, Dexamethasone 0.1% Ophthalmic drops, suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3%, 1 drop every 2 hours for 2 days then 4 times daily for 5 days
Study: 17687151
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CR)
Study: 12096449
Drug: Cognitive‐behavioural treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural treatment combined with interventions designed to improve treatment compliance
Study: 12096449
Drug: Cognitive‐behavioural treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural treatment
Study: 2297107
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural fentanyl infusion
Study: 2297107
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous fentanyl infusion
Study: 31280470
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 70 µg/day
Study: 2166377
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enoxaparin
Study: 2166377
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin
Study: 21909736
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enoxaparin (in-hospital)
Study: 21909736
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin (in-hospital)
Study: 25804941
Drug: G-CSF plus
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF plus plerixafor
Study: 23333777
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus G-CSF
Study: 31891833
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol (mean BAC: 0.03 g/dL) during moped riding simulation
Study: 18420099
Drug: Ezetimibe/Simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin (10/20 mg/day) + Niacin (titrated to 2 g/day)